Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Last trade$11.91
Day change-$0.545 (-4.38%)
Day range$11.75 – $12.47
Volume190,935
Market cap$1.62B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for MESO.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for MESO.
Recent news
Company coverage with links to the original publishers.
Mesoblast Limited presented at the ASX Investor Day in Melbourne, highlighting its transformation into a commercial-stage biotechnology company. The company outlined key value-creation priorities including expansion of its FDA-approved Ryoncil® therapy into adult acute graft-versus-host disease, advancement of rexlemestrocel-L for inflammatory chronic low back pain and cardiopulmonary indications, and disciplined capital deployment for commercial growth and late-stage development programs.
Mesoblast Limited announced board changes with the retirement of William Burns (after 12 years) and Philip Krause (since 2022). The company plans to recruit new directors with U.S. and global commercial expertise as it transitions to a revenue-generating commercial enterprise following the FDA approval and successful U.S. launch of Ryoncil® for pediatric steroid-refractory acute graft versus host disease.
Mesoblast Limited reported a 44% increase in net revenues to US$28 million for RYONCIL in Q1 FY2027, with an 86% improvement in net operational cash spend. The company completed patient enrollment in its Phase 3 pivotal trial for rexlemestrocel-L in chronic low back pain and received FDA alignment for a BLA filing for treatment of life-threatening GI bleeding in end-stage heart failure patients with LVADs. The company maintains US$99 million in cash and is expanding RYONCIL's use in adult steroid-refractory acute graft versus host disease.
Mesoblast Limited reported strong financial results for FY2026 with total revenue of US$120.3 million, driven by successful RYONCIL commercial launch generating US$115.2 million in net revenue. The company completed patient treatment in its Phase 3 trial for chronic low back pain (rexlemestrocel-L), with results expected mid-2027. Net losses were reduced 44% to US$57.5 million. The company is expanding RYONCIL into adult markets and developing next-generation CAR-MSC and oncolytic virus technologies.
Mesoblast Limited reported strong first-year commercial performance for Ryoncil® with Q4 net revenues of US$36M and full-year revenues of US$115M following FDA approval. The company is expanding Ryoncil® indications to adults with steroid-refractory acute GvHD and children with Duchenne muscular dystrophy. Additionally, Mesoblast achieved its target of 300 patients treated in the pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain and received FDA clearance for a registrational trial in adults with SR-aGvHD.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.